Search

Search Results
Results 711 - 720 of 898 for Platelet count
  • News - 11 Dec 2009
    Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, today announced that clinical data on ZEVALIN (ibritumomab tiuxetan) was presented at the...
  • News - 7 Dec 2009
    Clavis Pharma ASA announces that positive clinical data from its Phase II study with its lead cancer product candidate elacytarabine in patients with late-stage acute myeloid leukaemia (AML) was...
  • Drug - 16 Dec 2025
    Consumer Medicine Information (CMI) about Talvey intended for persons living in Australia.
  • Drug - 15 Dec 2025
    Consumer Medicine Information (CMI) about Tomudex intended for persons living in Australia.
  • Drug - 8 Dec 2025
    Consumer Medicine Information (CMI) about DBL Heparin Sodium intended for persons living in Australia.
  • Drug - 8 Dec 2025
    Consumer Medicine Information (CMI) about Heparin Injection intended for persons living in Australia.
  • Drug - 8 Oct 2025
    Consumer Medicine Information (CMI) about Onureg intended for persons living in Australia.
  • Drug - 15 Aug 2025
    Consumer Medicine Information (CMI) about Darzalex SC intended for persons living in Australia.
  • Drug - 18 Jul 2025
    Consumer Medicine Information (CMI) about Zavedos intended for persons living in Australia.
  • Drug - 6 Mar 2025
    Consumer Medicine Information (CMI) about Darzalex intended for persons living in Australia.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.